Drugs in Dev. Gastroenterology
Phase I
Belgium 
Lead Product(s) : Filgotinib
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Filgotinib, an orally administered, preferential JAK1 inhibitor, used in the induction and maintenance of remission in patients with Crohn’s disease (CD).
Product Name : Jyseleca
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2021
Lead Product(s) : Filgotinib
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Contact Us!
Reset All
